# PAPER DETAILS

TITLE: Evaluation of hematologic inflammation parameters and cranial magnetic resonance imaging findings in patients with trigeminal neuralgia AUTHORS: Demet Aygün, Hüseyin Dogu PAGES: 197-203 ORIGINAL PDF URL: https://dergipark.org.tr/tr/download/article-file/4244675

# HEALTH SCIENCES **MEDICINE**

# Evaluation of hematologic inflammation parameters and cranial magnetic resonance imaging findings in patients with trigeminal neuralgia

Demet Aygün Üstel<sup>1</sup>, DHüseyin Doğu<sup>2</sup>

<sup>1</sup>Department of Neurology, Faculty of Medicine, İstanbul Atlas University, İstanbul, Turkiye <sup>2</sup>Department of Neurosurgery, Faculty of Medicine, İstanbul Atlas University, İstanbul, Turkiye

**Cite this article as:** Aygün Üstel D, Doğu H. Evaluation of hematologic inflammation parameters and cranial magnetic resonance imaging findings in patients with trigeminal neuralgia. *J Health Sci Med.* 2025;8(2):197-203.

<b>Received:</b> 23.09.2024	•	Accepted: 26.01.2025	•	Published: 21.03.2025	
-----------------------------	---	----------------------	---	-----------------------	--

# ABSTRACT

**Aims:** This study aimed to evaluate the relationship between trigeminal neuralgia (TN) and hematological parameters, including leukocyte-based inflammatory indices, and to explore their association with cranial magnetic resonance imaging (MRI) findings. **Methods:** A retrospective analysis was conducted on 114 patients with newly diagnosed TN and 114 healthy control groups with comparable demographic characteristics. Clinical, laboratory, and cranial MRI data were collected from hospital records. White matter abnormalities were identified via cranial MRI, and inflammatory indices were calculated as follows: neutrophil-to-lymphocyte ratio (NLR)=Neutrophil count/lymphocyte count, platelet-to-lymphocyte ratio (PLR)=Platelet count/lymphocyte count, Systemic Immune-Inflammation Index (SII)=Platelet count×neutrophil count/lymphocyte count, and Systemic Inflammatory Response Index (SIRI)=Neutrophil count×monocyte count/lymphocyte count.

**Results:** TN patients showed significantly higher leukocyte counts  $(7.4\pm1.8 \text{ vs. } 6.0\pm1.9 \times 10^3/\mu\text{l}, \text{p}<0.001)$ , neutrophil counts  $(4.2\pm1.1 \text{ vs. } 2.8\pm0.8\times10^3/\mu\text{l}, \text{p}<0.001)$ , CRP levels (median: 2.6 vs. 0.8 mg/dl, p<0.001), and inflammatory indices (NLR, PLR, SII, and SIRI; p<0.001 for all) compared to control group. White matter abnormalities were detected in 16.7% of TN patients, predominantly in the frontal (11.4%) and parieto-occipital (7.0%) regions. Patients with white matter abnormalities exhibited significantly higher inflammatory indices than those without. Compared to other inflammatory parameters, SIRI demonstrated the highest diagnostic performance for TN (threshold: 0.7; sensitivity: 84.2%, specificity: 82.5%) and white matter abnormalities (threshold: 1.3; sensitivity: 78.9%, specificity: 82.1%).

**Conclusion:** Inflammatory markers, particularly SIRI, are significantly elevated in TN patients and are associated with white matter abnormalities. These markers may serve as useful non-invasive tools for predicting TN and related MRI findings. **Keywords:** Trigeminal neuralgia, inflammation markers, white matter lesions, cranial MRI, Inflammation Index

# INTRODUCTION

Trigeminal neuralgia (TN) is described as sudden, intense, brief, stabbing pain attacks, typically affecting one side of the face and localized to the distribution of one or more branches of the trigeminal nerve.<sup>1</sup> It typically occurs in middle and older age and is more common in women than in men.<sup>2,3</sup> However, the etiology and underlying mechanisms of TN remain insufficiently understood.<sup>4</sup>

Compression of the trigeminal nerve is linked to significant myelin erosion and disintegration due to inflammation, especially at the site of nerve indentation.<sup>5,6</sup> Structural changes related to this compression may impact the functionality of voltage-gated sodium (Nav) channels, which play a significant role in the onset of TN symptoms.<sup>7</sup> It has also been shown that changes in Nav expression play a role in the development of neuropathic and inflammatory pain.<sup>8,9</sup> Moreover, the cerebrospinal fluid of TN patients demonstrates significant increases in inflammatory mediators such as chemokines, proinflammatory cytokines, growth factors, and tumor necrosis factor superfamily, suggesting a pathophysiologic role for neuroinflammation.<sup>10,11</sup> Furthermore, neuroimaging studies conducted on TN patients indicate that neuroinflammation could be associated with brain structure and function such as white and gray matter volume changes.<sup>12,13</sup>

Previous rare studies have reported conflicting results regarding the association between systemic inflammatory indices, such as the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR), measured using a low-cost, more practical, and simpler method, and TN.<sup>14-16</sup> However, the relationship between systemic inflammatory markers and cranial magnetic resonance imaging (MRI) findings in these patients has not yet been investigated. This study aimed to assess the relationship between TN and hematological

Corresponding Author: Demet Aygün Üstel, demetaygun@yahoo.com



parameters, including leukocyte-based inflammation indices, and to examine their connection to cranial MRI findings.

# **METHODS**

# Ethics

Following the principles set forth in the Declaration of Helsinki, this single center retrospective study was conducted at the Atlas University Medicine Hospital Neurology Clinical from January 2021 to November 2023. The study received approval from the Üsküdar University Non-interventional Researches Ethics Committee (Date: 27.11.2023, Decision No: 2023-61). The local ethics committee did not require informed consent because the study was retrospective.

### **Study Population**

A total of 144 patients diagnosed with TN were retrospectively examined. The diagnosis of TN was determined according to the criteria of International Classification of Headache Disorders (ICHD3).<sup>1</sup> Patients with chronic conditions (cerebrovascular disease, central nervous system vasculitis, rheumatologic disease, hypertension, diabetes mellitus, chronic any diseases, hematologic disorders, acute inflammatory diseases), those with a history of TN, those with cranial MRI findings of pathologies such as masses or trauma sequelae, those who had undergone surgery in the past month prior to diagnosis, those using steroids, antibiotics, antivirals, antiplatelet, anticoagulant, or immunosuppressant drugs, those who were pregnant, and those with missing data were excluded from the study. After this exclusion process, 114 patients with newly diagnosed with TN were enrolled in this study. The control group, consisting of 114 healthy individuals who underwent check-up programs, had no comorbidities, had normal brain imaging results, and were matched with TN patients by age and sex, was also included in the study.

### **Study Protocol**

Demographic, clinical, and imaging data were obtained from the hospital's electronic information system and patient records. Blood samples and cranial MRI data for all patients were collected at the time of their initial hospital admission. Prior to starting any treatment, complete blood count and biochemical parameters were measured using venous blood samples taken after a 12-hour fasting period during outpatient evaluations. All samples were analyzed in a single laboratory following the same methodology outlined below. Pain severity was assessed by the patients using the Visual Analogue Scale (VAS), with scores ranging from 1 to 10.

### **Biochemical Analysis**

Venous blood samples were analyzed using a Cell-Dyn 3700 SL device (Abbott Diagnostics, Chicago, USA). Hemoglobin levels were measured photometrically, platelet count via the impedance method, and CRP levels using the immunoturbidimetric method. The inflammatory indices were respectively calculated as follows: NLR=Neutrophil count/lymphocyte count, PLR=Platelet count/lymphocyte count, Systemic Immune-Inflammation Index (SII)=Platelet count×neutrophil count/lymphocyte count, and Systemic Inflammatory Response Index (SIRI)=Neutrophil count× monocyte count/lymphocyte count.

# **Cranial MRI Evaluation**

The patients' cranial MRI images were retrospectively evaluated. All imaging were performed with a 1.5 Tesla MRI machine (Achieva, Philips Medical Systems, Best, The Netherlands). The MRI protocol consisted of various sequences: T1-weighted imaging (T1WI) in axial and sagittal planes, T2-weighted imaging (T2WI) in axial, coronal, and sagittal planes, along with axial and coronal fluid-attenuated inversion recovery (FLAIR). White matter and basal ganglia lesions were assessed using the age-related white matter changes (ARWMC) scale, which evaluates white matter lesions based on their size and location.<sup>17</sup> The brain was divided into five regions for assessment in both hemispheres: (1) frontal region: the anterior portion of the brain, located in front of the central sulcus; (2) parieto-occipital region: the parietal and occipital lobes combined; (3) temporal region: the lateral section of the brain, extending from the posterior part of the Sylvian fissure to the lateral ventricles; (4) infratentorial region: including the brainstem and cerebellum; and (5) basal ganglia and insula: covering the striatum, globus pallidus, thalamus, internal and external capsules, and insula. Lesions were graded as follows: grade 0: no lesions; grade 1: focal lesions; grade 2: lesions with a tendency to merge; grade 3: diffuse involvement of the entire region, with or without U-fiber involvement.

Hyperintense lesions measuring less than 5 mm and numbering between 4 and 12 in the periventricular white matter on cranial MRI were included in the study. Patients were categorized into those with and those without white matter lesions.

### **Statistical Analysis**

Data analysis was conducted using IBM SPSS Statistics for Windows, version 20.0 (IBM Corp., Armonk, NY, USA). Numerical variables with a normal distribution, as verified by Kolmogorov-Smirnov tests, are presented as mean±standard deviation (SD), while non-normally distributed variables are expressed as median values with interquartile ranges (25<sup>th</sup>-75<sup>th</sup> percentile). For group comparisons, the student's T test was used for normally distributed data, and the Mann-Whitney U test was applied for data not meeting normality assumptions. Categorical variables are shown as frequencies and percentages, with comparisons between groups performed using the chi-square or Fisher's exact tests. To identify independent predictors of TN, a multivariable logistic regression analysis was carried out using the backward Wald method. The receiver operating characteristic (ROC) curve analysis was employed to evaluate diagnostic performance, reporting the area under the curve (AUC), standard error (SE), sensitivity, and specificity. The Youden index method was used to determine the optimal cutoff values of hematological parameters or indices for predicting TN and the presence of white matter abnormalities. Comparisons of AUCs were made using a nonparametric approach based on the generalized U-statistics framework, with the covariance matrix estimation method described by DeLong et al.<sup>18</sup> Statistical significance was set at p<0.05 (\*) for all tests.

# RESULTS

The study included 114 control participants (mean age: 49.7±11.9 years) and 114 patients with TN (mean age: 49.5±13.7 years). The two groups had comparable age and gender distributions. The majority of patients with TN had right side dominance (66.7%). In the TN group compared to the control group, the mean leukocyte counts (7.4±1.8 vs.  $6.0\pm1.9\times10^3$  µl, p<0.001), mean red blood cells (RBC) ( $4.6\pm0.5$  vs.  $4.4\pm0.5\times10^6$  µl, p=0.011), mean neutrophil counts ( $4.2\pm1.1$  vs.  $2.8\pm0.8\times10^3$  µl, p<0.001), mean monocytes count ( $0.4\pm0.1$  vs.  $0.5\pm0.1\times10^3$  µl, p<0.001), and median CRP level (2.6 vs. 0.8 mg/dl, p<0.001) were higher, while the median lymphocyte counts was found to be lower ( $2.1\pm0.6$  vs.  $2.3\pm0.6\times10^3$  µl, p<0.001). Also, in the TN group, inflammation indices (NLR, PLR, SII, and SIRI) were found to be higher (**Table 1**).

The effects of hematological parameters and inflammation indices on TN were analyzed using multivariable regression models. Model I multivariable regression analysis included only hematological parameters. Model II multivariable regression analysis included leukocytes, RBC, CRP, NLR, and PLR, while lymphocyte subtypes were excluded due to high collinearity with NLR and PLR. Model III multivariable regression analysis included leukocytes, RBC, CRP, SII, and SIRI, while lymphocyte subtypes, NLR, and PLR were excluded due to high collinearity with SII and SIRI. Among these, Model III demonstrated superior performance in explaining the variance associated with TN compared to other models. Accordingly, increased CRP (OR=2.85, p<0.001) and SIRI (OR=13.48, p<0.001) levels were identified as independent predictors of TN (**Table 2**).

Cranial MRI revealed that 16.7% of TN patients exhibited white matter abnormalities. These lesions were predominantly located in the frontal region (11.4%), with fewer cases involving the parieto-occipital (7.0%) and temporal regions (0.9%). In patients with white matter abnormalities compared to those without, the median NLR (2.8 vs. 1.8, p<0.001), median PLR (138.8 vs. 125.3, p=0.016), median SII (751.6 vs. 454.4, p<0.001), and median SIRI (2.1 vs. 1.0, p<0.001) levels were higher. There was no significant difference in VAS scores between the groups (Table 3).

Table 1. Demographic and laboratory findings							
Variables	Control group n=114	Trigeminal neuralgia group n=114	р				
Age, years	49.7±11.9	49.5±13.7	0.873				
Gender, n (%)							
Female	85 (74.6)	85 (74.6)	0.000				
Male	29 (25.4)	29 (25.4)	0.999				
Side, n (%)							
Left	-	38 (33.3)					
Right	-	76 (66.7)	-				
Laboratory findings							
Leukocytes, $\times 10^3 \mu l$	6.0±1.9	$7.4{\pm}1.8$	< 0.001*				
RBC, ×10 <sup>6</sup> μl	4.4±0.5	4.6±0.5	0.011*				
Hemoglobin, g/dl	13.4±1.2	13.2±1.5	0.568				
Hematocrit, %	39.9±2.8	39.6±4.0	0.505				
Platelets, $\times 10^3 \mu l$	252.5±50.6	256.6±55.7	0.563				
Lymphocytes, ×10 <sup>3</sup> µl	2.3±0.6	2.1±0.6	< 0.001*				
Neutrophils, $\times 10^3$ µl	2.8±0.8	4.2±1.1	< 0.001*				
Monocytes, $\times 10^3 \mu l$	$0.4{\pm}0.1$	0.5±0.1	< 0.001*				
CRP, mg/dl	0.8 (0.1-2.3)	2.6 (2.1-3.3)	< 0.001*				
NLR	1.0 (0.9-1.6)	1.8 (1.6-2.6)	< 0.001*				
PLR	107.7 (90.2-120.9)	125.4 (106.6-148.7)	<0.001*				
SII	260.8 (228.3-392.6)	480.8 (370.0-668.5)	< 0.001*				
SIRI	0.5 (0.4-0.7)	1.0 (0.7-1.4)	< 0.001*				
VAS	-	9.0 (7.0-9.0)	-				
Cranial MRI findings,	n (%)						
White matter hyperin	itensity						
No	-	95 (83.3)	-				
Yes	-	19 (16.7)	-				
Side							
Frontal region	-	13 (11.4)	-				
Parieto-occipital r	egion -	8 (7.0)	-				
Temporal regior	1 -	1 (0.9)	-				

Data are mean±standard deviation or median (IQR), or number (%). \*p<0.05 indicates statistical significance. Abbreviations: RBC: Red blood cells, CRP: C-reactive protein, NLR: Neutrophil to lymphocyte ratio, PLR: Platelet to lymphocyte ratio, SII: Systemic Immune-Inflammation Index, SIRI: Systemic Inflammatory Response Index, VAS: Visual Analogue Scale, MRI: Magnetic resonance imaging

Table 2. Independent predictor of trigeminal neuralgia									
	Univariable regression		Model I regression		Model II regression		Model III regression		
Variables	OR (95% CI)	р	OR (95% CI)	р	OR (95% CI)	р	OR (95% CI)	р	
Leukocytes	1.55 (1.31-1.84)	< 0.001*	-	-	-	-	-	-	
RBC	2.01 (2.15-2.50)	0.015*	-	-	-	-	-	-	
Lymphocytes	0.43 (0.26-0.69)	< 0.001*	0.34 (0.15-0.78)	0.011*	Not includ	ing	Not includ	ing	
Neutrophils	4.72 (4.14-4.10)	< 0.001*	2.73 (1.69-4.40)	< 0.001*	Not includ	ing	Not includ	ing	
Monocytes	1.05 (1.03-1.08)	< 0.001*	1.05 (1.01-1.09) 0.006*		Not including		Not including		
CRP	3.25 (3.29-3.61)	< 0.001*	2.68 (1.79-4.00)	< 0.001*	3.08 (2.08-4.56)	< 0.001*	2.85 (1.96-4.13)	< 0.001*	
NLR	6.59 (6.63-6.97)	< 0.001*	Not includi	ng	7.03 (3.01-16.42)	< 0.001*	Not includ	ing	
PLR	1.02 (1.01-1.04)	0.001*	Not includin	ng	-	-	Not includ	ing	
SII	1.03 (1.01-1.05)	< 0.001*	Not including		Not including		-	-	
SIRI	20.66 (20.18-20.16)	< 0.001*	Not including		Not including		13.48 (4.43-40.95)	< 0.001*	
			Nagelkerke R <sup>2</sup> =	0.325	Nagelkerke R <sup>2</sup>	=0.354	Nagelkerke R <sup>2</sup>	=0.489	
The effects of age and gender were adjusted in the regression analysis. *p<0.05 indicates statistical significance. Abbreviations: OR: Odds ratio, CI: Confidence interval, RBC: Red blood cells, CRP: C-reactive protein, NLR: Neutrophil to lymphocyte ratio, PLR: Platelet to lymphocyte ratio, SII: Systemic Immune-Inflammation Index, SIRI: Systemic Inflammatory Response Index									

Table 3. Findings associated	l with white mat	ter in trigeminal	neuralgia	Table 4. Findings associat	ted with VAS score i	n trigeminal neura	lgia	
	White matter hyperintensity				VAS s			
Variables	No (n=95)	Yes (n=19)	р	Variables	Moderate (n=21)	Severe (n=93)	р	
Age, years	48.7±13.8	53.2±12.7	0.200	Age, years	49.0 (36.0-62.0)	51.0 (41.0-60.0)	0.994	
Gender, n (%)				Gender, n (%)				
Female	71 (74.7)	14 (73.7)	0.000	Female	14 (66.7)	71 (76.3)	0.259	
Male	24 (25.3)	5 (26.3)	0.923	Male	7 (33.3)	22 (23.7)	0.358	
Laboratory findings				Laboratory findings				
Leukocytes, ×10 <sup>3</sup> µl	7.1±1.5	8.9±2.2	< 0.001*	Leukocytes, ×10 <sup>3</sup> µl	7.1±1.5	7.5±1.8	0.313	
RBC, ×10 <sup>6</sup> μl	4.6±0.5	4.6±0.4	0.920	RBC, ×10 <sup>6</sup> μl	4.6±0.3	4.6±0.5	0.935	
Platelets, ×10 <sup>3</sup> µl	256.4±56.7	257.7±52.0	0.923	Platelets, $\times 10^3 \mu l$	274.7±48.6	252.5±56.7	0.100	
Lymphocytes, ×10 <sup>3</sup> µl	2.1 (1.8-2.5)	1.9 (0.8-2.2)	0.012*	Lymphocytes, ×10 <sup>3</sup> µl	2.1±0.4	2.0±0.6	0.817	
Neutrophils, ×10 <sup>3</sup> μl	4.0±1.0	4.8±1.1	0.004*	Neutrophils, $\times 10^3 \mu l$	4.0±1.2	4.2±1.0	0.559	
Monocytes, ×10 <sup>3</sup> μl	0.5±0.1	0.5±0.2	0.406	Monocytes, ×10 <sup>3</sup> µl	0.5±0.1	$0.5 \pm 0.1$	0.572	
CRP, mg/dl	2.1 (1.9-2.8)	2.6 (2.4-3.4)	0.036*	CRP, mg/dl	2.6 (2.2-3.0)	2.5 (2.0-3.4)	0.405	
NLR	1.8 (1.6-2.3)	2.8 (2.4-5.5)	< 0.001*	NLR	1.8 (1.6-2.4)	1.8 (1.6-2.7)	0.324	
PLR	125.3 (102.1-144.2)	138.8 (112.1-335.1)	0.016*	PLR	135.3 (110.1-177.2)	124.0 (104.4-148.7)	0.236	
SII	454.4 (356.0-640.5)	751.6 (522.8-1476.6)	< 0.001*	SII	529.8 (369.8-629.6)	460.0 (370.7-669.5)	0.759	
SIRI	1.0 (0.7-1.2)	2.1 (1.4-2.4)	< 0.001*	SIRI	0.9 (0.6-1.3)	1.0 (0.7-1.4)	0.236	
VAS	8.4±1.4	8.2±1.3	0.489	White matter hyperinten	sity			
Moderate	17 (17.9)	4 (21.1)		No	17 (81.0)	78 (83.9)	0 746	
Severe	78 (82.1)	15 (78.9)	0.746	Yes	4 (19.0)	15 (16.1)	0.740	
Data are mean±standard deviation o significance. Abbreviations: CRP: C- Platelet to lymphocyte ratio, RBC: 1 SIRI: Systemic Inflammatory Respon	Data are mean±standard deviation or median (IQR), or number (%), *p<0.05 indicates statistical significance. Abbreviations: CRP: C-reactive protein, NLR: Neutrophil to lymphocyte ratio, PLR: Platelet to lymphocyte ratio, RBC: Red blood cells, SII: Systemic Immune-Inflammation Index, SIRI: Systemic Inflammatory Response Index, VAS: Visual Analogue Scale							

Demographic and clinical parameters showed no significant differences in patients with moderate and severe pain (Table 4).

**Table 5** presents the diagnostic performance of inflammatorymarkers in predicting TN and white matter abnormalities.

Table 5. Diagnostic performance of inflammation parameters in predicting trigeminal neuralgia and white matter							
Variable	AUC±SE	95% CI	Sens. (%)	Spec. (%)	Threshold values		
Trigeminal neuralgia (vs. control)							
Leukocytes	0.723±0.03	0.658-0.789	57.0	81.6	$\geq 7 \times 10^3  \mu l$		
RBC	$0.617 {\pm} 0.04$	0.545-0.690	43.9	84.2	≥4.7×10 <sup>6</sup> µl		
Platelets	$0.512 \pm 0.04$	0.437-0.587	28.9	90.4	≥278×10³ µl		
Neutrophils	$0.759 \pm 0.03$	0.710-0.808	70.7	72.5	$\geq$ 3.2×10 <sup>3</sup> µl		
Lymphocytes	0.625±0.04	0.553-0.698	70.2	21.1	≤1.85×10³ µl		
Monocytes	$0.566 \pm 0.04$	0.492-0.641	77.2	42.1	$\geq 0.4 \times 10^3 \ \mu l$		
NLR	0.741±0.03	0.689-0.793	69.3	79.5	≥1.7		
PLR	$0.638 \pm 0.04$	0.566-0.709	56.1	80.7	≥122.8		
SII	0.811±0.03	0.767-0.875	80.6	61.4	≥268.5		
SIRI	0.832±0.03	0.776-0.886	84.2	82.5	≥0.7		
CRP	0.782±0.03	0.721-0.831	74.3	78.3	>2.4 mg/dl		
White matter hyperintensity (vs. normal MR	CI)						
Leukocytes	$0.744 \pm 0.07$	0.609-0.879	63.2	82.1	8.7×10³ μl		
Neutrophils	0.683±0.06	0.589-0.767	71.2	47.8	$>3.50 \times 10^{3} \mu l$		
Lymphocytes	0.675±0.07	0.581-0.759	42,1	85.8	≤1.23×10³ µl		
NLR	$0.799 \pm 0.06$	0.674-0.924	78.9	80.0	≥2.3		
PLR	0.675±0.07	0.533-0.817	42.1	95.8	≥187.8		
SII	$0.789 \pm 0.06$	0.661-0.916	89.5	55.8	≥476.7		
SIRI	0.831±0.06	0.717-0.945	78.9	82.1	≥1.3		
CRP	0.618±0.03	0.546-0.691	70.2	57.9	>2.8 mg/dl		
*p<0.05 indicates statistical significance. Abbreviations: AU lymphocyte ratio, PLR: Platelet to lymphocyte ratio, SII: Sys	C: Area under the curve, SE stemic Immune-Inflammati	: Standard error, CI: Confidenc ion Index, SIRI: Systemic Infla	e interval, Sens: Sensitivity, S mmatory Response Index, Cl	pec: Specificity, RBC: Red RP: C-reactive protein, MR	plood cells, NLR: Neutrophil to I: Magnetic resonance imaging		

Among the markers, SIRI showed the highest performance. For TN, a SIRI threshold of 0.7 provided 84.2% sensitivity and 82.5% specificity. For white matter abnormalities, a threshold of 1.3 yielded 78.9% sensitivity and 82.1% specificity.

# DISCUSSION

To the best of our knowledge, this study is one of the few to investigate the relationship between TN, hematological inflammation parameters, and cranial MRI findings. Additionally, this study is the first to assess the association between SII, SIRI and TN. TN patients had higher leukocytebased inflammatory indices, and SIRI was found to be an independent predictor. In the TN cohort, inflammatory indices were elevated in patients with white matter abnormalities. Furthermore, SIRI demonstrated superior diagnostic performance compared to other inflammatory markers in predicting both TN and white matter abnormalities.

Previous research has indicated that the progression of TN is induced by inflammatory factors such as tumor necrosis factor, C-C motif chemokine ligand 2 (CCL2), interleukin (IL)-6, and transient receptor potential ankyrin 1 (TRPA1).<sup>19-22</sup> In an experimental model of trigeminal neuropathic pain caused by infraorbital nerve constriction, it was proposed that painlike behaviors are facilitated by the TRPA1 channel. This is linked to oxidative stress byproducts secreted by monocytes and macrophages concentrated around the site of the nerve injury.<sup>23</sup> Following tissue damage, pro-inflammatory cytokines are expressed by neutrophils, lymphocytes, monocytes and macrophages.<sup>24</sup> This highlights the role of immune cells in the heightened pro-inflammatory cytokine levels observed in TN patients after neurological injury.<sup>10,20</sup> In line with these findings, lymphocyte levels and their subtypes were elevated in TN patients relative to the control group.<sup>14</sup> This finding aligns with the elevated CRP levels in TN patients, which serve as a recognized marker of immuneinflammatory status.<sup>25,26</sup>

Blood parameters are routinely accessible laboratory tests during the initial phase of hospital admission, and they are universally obtained within the first hour.<sup>27</sup> In clinical practice, an easily assessable biomarker could be a crucial predictor for diagnosing central nervous system diseases, assessing prognosis, or identifying high-risk patients. A recent study investigated the role of preoperative inflammatory markers in patients with newly diagnosed glioma, schwannoma, meningioma, pituitary adenoma, or trigeminal neuralgia. The study demonstrated that meningioma and glioma patients had elevated NLR and PLR levels, while TN patients showed levels comparable to the healthy control group.<sup>28</sup> In the existing literature, there are contradictory findings concerning NLR and PLR levels when comparing TN patients with healthy control groups. In a retrospective study conducted in China, newly diagnosed TN patients were reported to have higher NLR and PLR levels than healthy controls.<sup>14</sup> Studies conducted in Turkey have indicated that TN patients show no significant differences in NLR or PLR levels compared to the healthy control group.<sup>15,16</sup> In these studies, the disease duration was either unspecified or focused on patients with chronic disease. Thus, variations among the studies may stem from differences in patient selection.

The current study revealed that newly diagnosed TN patients displayed significantly higher NLR and PLR levels when compared to healthy controls. Furthermore, NLR levels provided superior diagnostic performance over PLR levels in the prediction of TN. These results align with the role of neutrophils and lymphocytes in driving elevated pro-inflammatory cytokine production in TN patients.<sup>24</sup> However, in this cohort, more comprehensive inflammatory indices could better represent the innate immune reaction to nerve damage. SIRI, incorporating monocytes, was identified as an independent predictor of TN and outperformed other inflammatory indices in diagnostic performance. Moreover, the regression model that incorporated SIRI provided a better explanation of the variance in TN than models that including NLR, PLR, or their components. The superior diagnostic performance of SIRI can likely be explained by the involvement of its components in the neuroinflammatory processes triggered by the cytokine-chemokine network, which plays a key role in the pathogenesis of TN.<sup>29,30</sup> Moreover, platelets and platelet-related indices, such as PLR, appear to play a less significant role in the pathogenesis of TN compared to neutrophils or monocytes. This observation aligns with findings from previous studies, which reported no significant differences in platelet levels between TN patients and healthy controls.<sup>14,15</sup> While platelets contribute to the inflammatory milieu by releasing pro-inflammatory mediators like platelet-derived growth factor, their involvement may be less pronounced in the neuroinflammatory processes central to TN.<sup>31</sup> In contrast, neutrophils and monocytes, through their direct roles in cytokine-chemokine signaling and innate immune activation, are likely the primary drivers of inflammation and nerve damage in TN.<sup>31</sup> Consequently, platelet-related indices such as PLR may have limited utility in capturing the complex inflammatory mechanisms underlying TN when compared to indices like NLR or SIRI, which incorporate more dominant immune cell types in the neuroinflammatory response.

Previous research has revealed the presence of white matter abnormalities in TN patients, likely resulting from the effects of chronic pain and peripheral nerve damage.<sup>32-34</sup> Previous studies on TN patients have demonstrated white matter integrity disruption in the right anterior limb and left genu of the internal capsule, the bilateral superior corona radiata, the splenium and body of the corpus callosum, the bilateral posterior corona radiate, and the left posterior thalamic radiation.35,36 Consistent with these studies, white matter hyperintensities were predominantly located in the frontal and parieto-occipital regions, indicating potential cognitive-emotional or motor function impairment. The exact mechanism underlying the impact of TN on brain white matter integrity has yet to be determined. A previous study found reduced fractional anisotropy in TN patients, linked to increased radial diffusivity, suggesting that demyelination and neuroinflammation might disrupt white matter integrity in these patients.<sup>37</sup> This may explain the higher inflammatory indices observed in TN patients with white matter abnormalities. Studies conducted on other neurological diseases also support the current findings. A study on Parkinson's patients showed that they had lower

fractional anisotropy and higher radial and mean diffusivity compared to healthy control group. The observed reductions in fractional anisotropy and elevations in radial and mean diffusivity were linked to elevated systemic inflammatory markers, including lymphocyte and granulocyte apoptosis.<sup>38</sup> In autopsied brains of monkeys induced with 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine, an increased infiltration of lymphocyte function-associated antigen 1-positive leukocytes was observed in the substantia nigra.<sup>39</sup> The activation of microglia, facilitated by leukocytes and cytokines, may lead to demyelination and the development of neuritis, ultimately affecting the structural integrity of white matter.<sup>38</sup> On the other hand, pain severity did not correlate with either white matter lesions or inflammatory indices. This finding suggests that in newly diagnosed TN patients, the connection between white matter lesions and neuroinflammatory processes is independent of the mechanisms driving pain intensity.

#### Limitations

This study has several limitations, including its retrospective design, single-center nature, and relatively small sample size, which may limit the generalizability of the findings. Additionally, the absence of advanced immunological analyses such as cytokine profiling or flow cytometry prevents a more detailed exploration of systemic and neuroinflammatory mechanisms. Furthermore, cranial MRI assessments did not include evaluations of gray matter lesions or cortical thickness, which could provide deeper insights into structural brain changes associated with TN. Future studies with larger, multicenter cohorts and the integration of advanced imaging and immunological techniques are needed to overcome these limitations and better understand the pathophysiology of TN.

#### **CONCLUSION**

This study revealed that inflammatory indices were significantly higher in TN patients compared to healthy controls. Furthermore, white matter lesions were associated with elevated inflammation indices, pointing to a potential connection between neuroinflammation and structural alterations in the brain. SIRI demonstrated the highest diagnostic accuracy among inflammatory markers in predicting TN and white matter abnormalities, highlighting its potential utility as both a diagnostic and prognostic screening non-invasive tool for TN.

### ETHICAL DECLARATIONS

#### **Ethics Committee Approval**

The study was carried out with the permission of the Üsküdar University Non-interventional Researches Ethics Committee (Date: 27.11.2023, Decision No: 2023-61).

#### **Informed Consent**

Because the study was designed retrospectively, no written informed consent form was obtained from patients.

#### **Referee Evaluation Process**

Externally peer-reviewed.

#### **Conflict of Interest Statement**

The authors have no conflicts of interest to declare.

#### **Financial Disclosure**

The authors declared that this study has received no financial support.

#### **Author Contributions**

All of the authors declare that they have all participated in the design, execution, and analysis of the paper, and that they have approved the final version.

#### REFERENCES

- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3<sup>rd</sup> edition. *Cephalalgia*. 2018;38(1):1-211. doi:10.1177/0333102417738202
- Montano N, Conforti G, Di Bonaventura R, Meglio M, Fernandez E, Papacci F. Advances in diagnosis and treatment of trigeminal neuralgia. *Ther Clin Risk Manag.* 2015;11:289-299. doi:10.2147/TCRM.S37592
- Jones MR, Urits I, Ehrhardt KP, et al. A comprehensive review of trigeminal neuralgia. *Curr Pain Headache Rep.* 2019;23(10):74. doi:10. 1007/s11916-019-0810-0
- 4. Chen Q, Yi DI, Perez JNJ, et al. The molecular basis and pathophysiology of trigeminal neuralgia. *Int J Mol Sci.* 2022;23(7):3604. doi:10.3390/ijms 23073604
- PekerS, KurtkayaO, UzunI, PamirMN. Microanatomyofthe central myelinperipheral myelin transition zone of the trigeminal nerve. *Neurosurgery*. 2006;59(2):354-359. doi:10.1227/01.NEU.0000223501.27220.69
- Love S, Hilton DA, Coakham HB. Central demyelination of the 5<sup>th</sup> nerve root in trigeminal neuralgia associated with vascular compression. *Brain Pathol.* 1998;8(1):1-11. doi:10.1111/j.1750-3639.1998.tb00126.x
- Wang J, Ou SW, Wang YJ. Distribution and function of voltage-gated sodium channels in the nervous system. *Channels (Austin)*. 2017;11(6): 534-554. doi:10.1080/19336950.2017.1380758
- Laedermann CJ, Abriel H, Decosterd I. Post-translational modifications of voltage-gated sodium channels in chronic pain syndromes. *Front Pharmacol.* 2015;6:263. doi:10.3389/fphar.2015.00263
- 9. Levinson SR, Luo S, Henry MA. The role of sodium channels in chronic pain. *Muscle Nerve*. 2012;46(2):155-165. doi:10.1002/mus.23314
- 10. Ostertag C, Friedman TN, Keough MB, Kerr BJ, Sankar T. Heightened presence of inflammatory mediators in the cerebrospinal fluid of patients with trigeminal neuralgia. *Pain Rep.* 2023;8(6):e1117. doi:10.1097/PR9. 000000000001117
- Ericson H, Abu Hamdeh S, Freyhult E, et al. Cerebrospinal fluid biomarkers of inflammation in trigeminal neuralgia patients operated with microvascular decompression. *Pain.* 2019;160(11):2603-2611. doi: 10.1097/j.pain.000000000001649
- Wang Y, Cao DY, Remeniuk B, Krimmel S, Seminowicz DA, Zhang M. Altered brain structure and function associated with sensory and affective components of classic trigeminal neuralgia. *Pain.* 2017;158(8): 1561-1570. doi:10.1097/j.pain.00000000000951
- Obermann M, Rodriguez-Raecke R, Naegel S, et al. Gray matter volume reduction reflects chronic pain in trigeminal neuralgia. *Neuroimage*. 2013;74:352-358. doi:10.1016/j.neuroimage.2013.02.029
- 14. Yao Y, Chang B, Li S. Relationship of inflammation with trigeminal neuralgia. *J Craniofac Surg.* 2020;31(2):e110-e113. doi:10.1097/SCS.0000 000000005879
- Altunisik E, Tak AZA. Comparison of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients diagnosed with trigeminal neuralgia and healthy controls. *Ann Med Res.* 2021;28(4):704-708. doi: 10.5455/annalsmedres.2020.05.437
- 16. Tuncer Z, Akbulut N, Ekmekçi UC, Çirkinoğlu GG, Öztürk V, Erkin Y. Monocyte to high-density lipoprotein ratio and neutrophil to lymphocyte ratio in trigeminal neuralgia patients: a retrospective cohort study: MHR and NLR in trigeminal neuralgia. *J Surg Med.* 2023; 7(9):568-573. doi.org/10.28982/josam.7884
- Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for agerelated white matter changes applicable to MRI and CT. *Stroke*. 2001; 32(6):1318-22. doi:10.1161/01.str.32.6.1318

- DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*. 1988;44(3):837-845. doi.org/10. 2307/2531595
- Demartini C, Greco R, Zanaboni AM, et al. Antagonism of transient receptor potential ankyrin type-1 channels as a potential target for the treatment of trigeminal neuropathic pain: study in an animal model. *Int J Mol Sci.* 2018;19(11):3320. doi:10.3390/ijms19113320
- 20. Lu ZY, Fan J, Yu LH, Ma B, Cheng LM. The up-regulation of TNF-alpha maintains trigeminal neuralgia by modulating MAPKs phosphorylation and BKCa channels in trigeminal nucleus caudalis. *Front Cell Neurosci.* 2021;15:764141. doi:10.3389/fncel.2021.764141
- 21. Zhang ZJ, Dong YL, Lu Y, Cao S, Zhao ZQ, Gao YJ. Chemokine CCL2 and its receptor CCR2 in the medullary dorsal horn are involved in trigeminal neuropathic pain. *J Neuroinflammation*. 2012;9:136. doi:10. 1186/1742-2094-9-136
- 22. Liu MX, Zhong J, Xia L, Dou NN, Li ST. A correlative analysis between inflammatory cytokines and trigeminal neuralgia or hemifacial spasm. *Neurol Res.* 2019;41(4):335-340. doi:10.1080/01616412.2018.1564188
- Trevisan G, Benemei S, Materazzi S, et al. TRPA1 mediates trigeminal neuropathic pain in mice downstream of monocytes/macrophages and oxidative stress. *Brain.* 2016;139(Pt 5):1361-1377. doi:10.1093/brain/ aww038
- 24. Tecchio C, Micheletti A, Cassatella MA. Neutrophil-derived cytokines: facts beyond expression. *Front Immunol.* 2014;5:508. doi:10.3389/ fimmu.2014.00508
- Algul FE, Unver FB. Relationship between trigeminal neuralgia and the C-reactive protein/albumin ratio. *Turk J Neurol.* 2024;30(3):134-140. doi:10.55697/tnd.2024.134
- 26. Lai S, Li H, Xing Y, Wu D, Wang L, Liang Q. Exploring the role of inflammatory biomarkers in trigeminal neuralgia. *Brain Behav Immun Health.* 2024;43:100930. doi:10.1016/j.bbih.2024.100930
- 27. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J.* 2018;39(2): 119-177. doi:10.1093/eurheartj/ehx393
- Chen F, Chao M, Huang T, et al. The role of preoperative inflammatory markers in patients with central nervous system tumors, focus on glioma. *Front Oncol.* 2022;12:1055783. doi:10.3389/fonc.2022.1055783
- Liu Y, Tanaka E. Pathogenesis, diagnosis, and management of trigeminal neuralgia: a narrative review. J Clin Med. 2025;14(2):528. doi:10.3390/ jcm14020528
- 30. Lee GW, Son JY, Lee AR, Ju JS, Bae YC, Ahn DK. Central VEGF-A pathway plays a key role in the development of trigeminal neuropathic pain in rats. *Mol Pain*. 2019;15:1744806919872602. doi:10.1177/1744806919872602
- Patil S, Testarelli L. Assessment of growth factors, cytokines, and cellular markers in saliva of patients with trigeminal neuralgia. *Molecules*. 2021;26(10):2964. doi:10.3390/molecules26102964
- 32. Liu Y, Li J, Butzkueven H, et al. Microstructural abnormalities in the trigeminal nerves of patients with trigeminal neuralgia revealed by multiple diffusion metrics. *Eur J Radiol.* 2013;82(5):783-786. doi:10.1016/ j.ejrad.2012.11.027
- 33. Wang Y, Li D, Bao F, Guo C, Ma S, Zhang M. Microstructural abnormalities of the trigeminal nerve correlate with pain severity and concomitant emotional dysfunctions in idiopathic trigeminal neuralgia: a randomized, prospective, double-blind study. *Magn Reson Imag.* 2016;34(5):609-616. doi:10.1016/j.mri.2015.11.013
- 34. DeSouza DD, Hodaie M, Davis KD. Abnormal trigeminal nerve microstructure and brain white matter in idiopathic trigeminal neuralgia. *Pain*. 2014;155(1):37-44. doi:10.1016/j.pain.2013.08.029
- 35. Wu M, Jiang X, Qiu J, Fu X, Niu C. Gray and white matter abnormalities in primary trigeminal neuralgia with and without neurovascular compression. J Headache Pain. 2020;21(1):136. doi:10.1186/s10194-020-01205-3
- 36. Moayedi M, Hodaie M. Trigeminal nerve and white matter brain abnormalities in chronic orofacial pain disorders. *Pain Rep.* 2019;4(4): e755. doi:10.1097/PR9.00000000000755
- 37. Liu J, Zhu J, Yuan F, Zhang X, Zhang Q. Abnormal brain white matter in patients with right trigeminal neuralgia: a diffusion tensor imaging study. J Headache Pain. 2018;19(1):46. doi:10.1186/s10194-018-0871-1

- Chiang PL, Chen HL, Lu CH, et al. White matter damage and systemic inflammation in Parkinson's disease. *BMC Neurosci*. 2017;18(1):48. doi: 10.1186/s12868-017-0367-y
- Miklossy J, Doudet DD, Schwab C, Yu S, McGeer EG, McGeer PL. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. *Exp Neurol.* 2006;197(2):275-283. doi:10.1016/j.expneurol. 2005.10.034